Truist Securities Reiterates Buy Rating on Voyager Therapeutics (VYGR): 'evolving into a platform-agnostic, CNS disease focused biotech'
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating on Voyager Therapeutics (NASDAQ: VYGR)The analyst commented, "The highly anticipated Tau ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
